Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach

NCT02008721 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

92

Enrollment

OTHER

Sponsor class

Conditions

Multiple System Atrophy

Interventions

DRUG: EGCG as putative neuroprotective agent
DRUG: Placebo

Sponsor

Dr. Johannes Levin

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]